

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: March 10, 2009

Electronic Signature for A. Jacqueline Wizeman, Ph.D.: /A. Jacqueline Wizeman/

Docket No.: EISN-018US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kenichi Chiba *et al.*

Application No.: 10/507,067

Confirmation No.: 8892

Filed: November 10, 2004

Art Unit: 1626

For: MACROCYCLIC COMPOUNDS USEFUL
AS PHARMACEUTICALS

Examiner: S. Young

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

The Examiner is also advised that the following commonly owned patents and applications contain subject matter that may be related to the present application.

Application No.	Filing Date	Attorney Docket No.	Status
10/657,910	09-09-2003	EISN-018CP	Pending
12/180,408	07-25-2008	EISN-003	Pending
12/180,423	07-25-2008	EISN-012	Pending

Applicants have supplied herewith a partial file history of U.S. Serial No. 10/657,910. Applicants understand that the Examiner can access papers from the prosecution of the other cited cases electronically via PAIR. However, if the Examiner has difficulty obtaining papers from that source he is invited to call the undersigned who will be happy to supply them.

This Information Disclosure Statement is filed more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. EISN-018US.

Dated: March 10, 2009

Respectfully submitted,

Electronic signature: /A. Jacqueline Wizeman/
A. Jacqueline Wizeman, Ph.D.
Registration No.: 62,307
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant